STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer

Author:

Saeed Anwaar1,Tabernero Josep2,Parikh Aparna3,den Eynde Marc Van45,Karthaus Meinolf6,Gerlinger Marco78,Wang Zhong9,Wang Guan9,Smith Robina9,Hecht J Randolph10ORCID

Affiliation:

1. University of Pittsburgh Medical Center (UPMC) & UPMC Hillman Cancer Center, Pittsburgh, PA, USA

2. Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain

3. Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA

4. Institut Roi Albert II, Department of Medical Oncology Cliniques Universitaires St-Luc, Brussels, Belgium

5. Institut de Recherche Clinique et Experimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium

6. Department of Hematology & Oncology, Klinikum Neuperlach/Klinikum Harlaching, Munich, Germany

7. Barts Cancer Institute, Queen Mary University of London, UK

8. Gastrointestinal Cancer Centre, St Bartholomew's Hospital, London, UK

9. Exelixis, Inc.Alameda, CA, USA

10. David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Santa Monica, CA, USA

Funder

Exelixis, Inc.

Publisher

Informa UK Limited

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3